Alimentary Pharmacology & Therapeutics

Article	Citations
Letter: risk of severe COVID‐19 outcomes associated with inflammatory bowel disease medications—reassuring insights from the United Kingdom PREPARE‐IBD multicentre cohort study	141
Editorial: is there a ‘precursor’ HCC lesion and can it be detected by hepatobiliary contrast‐enhanced magnetic resonance imaging? Authors' reply	138
Letter: Ozanimod and latent tuberculosis	137
Editorial: coeliac disease follow‐up guided by gluten immunogenic peptides—are we there yet? Authors' reply	111
Editorial: liver disease in secondary care—‘money or your life’. Authors' reply	102
Letter: is wireless oesophageal pH monitoring the best technique to evaluate night‐time reflux?	79
	71
Editorial: risk of pneumonia in IBD—reading between the lines!	70
Editorial: biomarkers for alcohol‐related liver fibrosis—almost there?	67
Letter: ductular reaction is a risk factor for prognosis of chronic hepatitis B complicated with non‐alcoholic fatty liver disease	67
Editorial: STAT3 phosphorylation for tofacitinib monitoring in ulcerative colitis—a step towards precision medicine?	66
Editorial: switching to tenofovir alafenamide monotherapy is effective and safe for other nucleos(t)ide analogues‐treated patients with chronic hepatitis B	66
Editorial: concurrence of coeliac disease with inflammatory bowel disease – is big data the final arbiter? Authors' reply	65
Editorial: ustekinumab during pregnancy ‐ reassuring but still not enough	64
Letter: Elderly onset inflammatory bowel disease—Treat to target approach is still warranted	63
Editorial: clinical outcomes in lean NAFLD – the devil is in the details. Authors' reply	62
Letter: time to consider Pneumocystis jirovecii pneumonia prophylaxis in treatment of autoimmune hepatitis	62
Editorial: tradipitant has promise for treating gastroparesis but leaves gastric function alone—authors’ reply	58
Letter: enhancing training opportunities for upper GI bleeding in Sheffield ‐ a UK transferable model? Authors' reply	58
Letter: faecal microbiota transplant in Clostridioides difficile infection: learning from the common water hyacinth	58
Editorial: rectal hyposensitivity in patients with hypermobile Ehlers‐Danlos syndrome and constipation—authors' reply	56
Development of a model to identify patients who do not need oesophageal biopsies when eosinophilic oesophagitis is suspected	55
Editorial: Plants against animals	55
Colorectal cancer in elderly‐onset inflammatory bowel disease: a 1969–2017 Scandinavian register‐based cohort study	55
Letter: Positivity of High‐Sensitivity HBsAg Test Was Significantly Associated With Poor Prognosis in Patients With Non‐HBV‐Related HCC	54

Editorial: Updated epidemiology of steatotic liver disease in people withHIVin the United States—Authors' reply	53
Letter: Allostatic load—A potential key in the development of inflammatory bowel disease	52
Editorial: Advanced glycation end products ‐ a dietary culprit for IBD in the genetically susceptible?	52
Letter: Gut microbiota—An overlooked therapeutic target in the prevention of post‐operative recurrence of Crohn's disease	48
AP&T: Editors' Declarations of Interest	48
First in human randomised trial of J2H‐1702: A novel 11β‐hydroxysteroid dehydrogenase type 1 inhibitor for non‐alcoholic steatohepatitis treatment	48
Positivity of high‐sensitivity HBsAg test, not previous HBV infection, indicates poor prognosis in patients with non‐HBV‐related HCC	48
Editorial: Revisit the causes and long‐term outcomes in cirrhosis patients	46
Editorial: Will MRI‐PDFF become the new standard for steatosis assessment in NAFLD? Authors' reply	46
	46
Issue Information	45
Letter: practical considerations for nonselective beta‐blocker therapy in portal hypertension	45
Editorial: dietary interventions to understand and treat primary sclerosing cholangitis—is gluten‐free diet a starting point?	45
Low socioeconomic status exacerbates unmet health‐related needs in patients with autoimmune hepatitis	45
Editorial: Can we predict or not predict response to hypnotherapy? That is the question	44
Issue Information	43
Editorial: Mesenchymal Stem Cell Therapy for Perianal Fistulising Crohn's Disease—Effective or Hype?	42
Letter: Real‐Life Evaluation of Effectiveness of Mesenchymal Stem Cell Treatment in Fistulising Crohn's Disease Emphasises Importance of Appropriate Patient Selection and Centre Expertise—Authors' Rep	42
	41
Editorial: Assessing advanced fibrosis in metabolic‐associated steatotic liver disease—TheMAFLDfibrosis score	41
Letter: Potential confounders might exaggerate the risk of rheumatoid arthritis in patients with microscopic colitis	41
Safety of an investigational formulation of budesonide (budesonide oral suspension) for eosinophilic oesophagitis: an integrated safety analysis of six phase 1–3 clinical trials	40
Editorial: The future of managing drug induced liver injury	40
Letter: Critical appraisal of biologic therapy in early ulcerative colitis management—Addressing study limitations and the role of psychological resilience—Authors' reply	40
Diagnostic Accuracy of an Add‐On, Blood‐Based Screening Test for Colorectal Cancer in Two Established Screening Programmes	39
Meta‐Analysis: Pregnancies With Inflammatory Bowel Disease Complicated by Intrahepatic Cholestasis of Pregnancy	39
Clinical Trial: Effect of Abdominal Vibration Combined With Walking Exercise Programme on Bowel Preparation in Older Patients With Constipation	39
Cost‐effectiveness of an adjuvanted recombinant zoster vaccine in adults with inflammatory bowel disease	38
Prevalence, symptoms and risk factor profile of rumination syndrome and functional dyspepsia: a population‐based study	38
Liver biopsy in the real world—reporting, expert concordance and correlation with a pragmatic clinical diagnosis	38
Longitudinal changes in renal function in patients with chronic hepatitis B on antiviral treatment	37
Prevalence and clinical characteristics of patients with metabolic dysfunction‐associated fatty liver disease with hepatitis C virus infection—a population‐based study	37
No value of non‐selective beta‐blockers after TIPS‐insertion	37
Decreased secondary faecal bile acids in children with ulcerative colitis and Clostridioides difficile infection	37
Liver resection versus microwave ablation for hepatocellular carcinoma in ideal candidates for ablation per Barcelona Clinic Liver Cancer staging: a propensity score matching and inverse probability o	35
Gut‐brain axis dysfunction underlies FODMAP‐induced symptom generation in irritable bowel syndrome	35
Systematic review and meta‐analysis: the incidence and prevalence of paediatric coeliac disease across Europe	35
Healthcare burden and outcomes of hepatorenal syndrome among cirrhosis‐related hospitalisations in the US	34
Editorial: Inflammatory Bowel Disease and Dietary Emulsifiers—A Conundrum That Continues. Authors' Reply	34
Review article: Emerging insights into the epidemiology, pathophysiology, diagnostic and therapeutic aspects of eosinophilic oesophagitis and other eosinophilic gastrointestinal diseases	34
Editorial: Feeling better about NASH—Authors' reply	33
Schizophrenia and risk of new‐onset inflammatory bowel disease: a nationwide longitudinal study	33
Letter: the diagnostic value of ultrasound‐based versus CT‐based sarcopenia measurement in cirrhosis	33
Characterisation of patients with supine nighttime reflux: observations made with prolonged wireless oesophageal pH monitoring	33
Editorial: Rebuilding Rome—Revising Diagnostic Criteria for Irritable Bowel Syndrome	32
Letter: normalizing the ileoanal pouch—more than a one‐step technique. Authors' reply	32
Editorial: finding the ideal prokinetic for gastroparesis—we are not there yet	32
Clinical Trial: Treatment of Functional Dyspepsia According to Subtype Compared With Empirical Proton Pump Inhibitor	32
Editorial: changes of health‐related quality of life associated with hepatic disease severity and its improvement after treatment in NAFLD—authorsʼ reply	32
Editorial: determining disability in inflammatory bowel disease—“See(k) and you shall find”. Authors' reply	32

Letter: hereditary role in non‐alcoholic fatty liver disease	32
Letter: chronic HDV infection—is ignorance bliss? Authors' reply	31
Editorial: time to eat? Skipping breakfast in metabolic‐associated fatty liver disease	31
Letter: Baveno‐VI criteria to exclude large varices in patients with hepatocellular carcinoma—What have we learned?	31
Letter: response of eosinophilic oesophagitis to proton pump inhibitor therapy—the importance of biopsies at index endoscopy	31
Editorial: aspirin and NSAID for chemoprevention of hepatocellular carcinoma—ready for their use?	31
Letter: the hidden reasons of long‐term risk of upper gastrointestinal bleeding after Helicobacter pylori eradication	31
Editorial: testing for Epstein Barr virus and treating autoimmune hepatitis—still a long way to go! Authors' reply	31
Editorial: inconclusive diagnosis of GERD—are new parameters in impedance‐pH‐metry ready for clinical use?	30
	30
Letter: The importance of histological assessment—a further stride inSTRIDE. Authors' reply	30
Editorial: an elastography‐based two‐step approach to detect NAFLD with compensated advanced chronic liver disease—authors' reply	30
Letter: Safety after cessation of nucleos(t)ide analogue therapy in patients with chronic hepatitis B infection	30
Issue Information	30
Letter: fighting the battle but losing the war—inflammatory bowel disease and venous thromboembolism	30
Letter: diet‐responsive or just diet‐adherent in eosinophilic oesophagitis. Where is the dietitian?	30
Trends in risk factor control and treatment among patients with non‐alcoholic fatty liver disease and type 2 diabetes between 2000 and 2020: A territory‐wide study	29
Editorial: The prevalence and outcomes of perianal Crohn's disease across treatment eras	29
Letter: Are we forgetting the importance of steatosis in steatotic liver disease? Authors' reply	29
Editorial: Diagnosis of GERD in patients with extra‐oesophageal symptoms—still a long way to go… Authors' reply'	29
Editorial: When and What to Ask—Capturing the Symptoms Experienced by Patients With PSC	28
	28
Editorial: reducing false alarms with oesophagogastric junction outflow obstruction	28
Editorial: Decoding ACLF—Sub‐Phenotyping to Advance Precision Medicine in Acute‐On‐Chronic Liver Failure	28
Letter: The Essential Role of Social Workers in Reducing Socioeconomic Disparities in Chronic Liver Disease	28
Clinical Trial: Study to Investigate the Efficacy and Safety of the Alpha‐2‐Delta Ligand PD‐217,014 in Patients With Irritable Bowel Syndrome	28
Letter: Optimising Prevention of Adverse Events and Antiviral Prophylaxis for HBV‐Infected HCC Patients Undergoing Immunotherapy	28
Letter: Clinical Trial Design Considerations for Hospitalised Patients With Ulcerative Colitis Flares and Application to Study Hyperbaric Oxygen Therapy in the NIDDK HBOT‐UC Cons	28
Sofosbuvir and risk of estimated glomerular filtration rate decline or end‐stage renal disease in patients with renal impairment	27
The impact of red blood cell transfusion practices on inpatient mortality in variceal and non‐variceal gastrointestinal bleeding patients: a 20‐year US nationwide retrospective analysis	27
Maladaptive weight control and eating behaviours in female adolescents/young adults are associated with increased risk of irritable bowel syndrome in adulthood: Results from the Growing Up Today Study	27
Progressive alcohol‐related liver fibrosis is characterised by imbalanced collagen formation and degradation	27
Autoimmune hepatitis and metabolic syndrome‐associated disease development: a U.S. cohort study	27
Editorial: Crystalising the burden of steatotic liver disease—Authors' reply	27
	27
Issue Information	27
Editorial: food insecurity, diet quality, racial and ethnic disparities in non‐alcoholic fatty liver disease	27
Letter: Albumin—Does formulation matter?	26
Letter: Association between chronic kidney disease, hepatitis B and antiviral treatments	26
Letter: the value of quality liver biopsy before initiation of corticosteroids for severe alcoholic hepatitis	26
Editorial: Negative impact of diabetes mellitus and obesity on the prognosis of patients with chronic liver disease—Authors' reply	26
Letter: Bisphosphonate effectiveness in patients with cirrhosis—an emulated clinical trial. Authors' reply	26
Letter: Third‐line therapy in acute severe ulcerative colitis, exploring the uncertainty and unanswered questions—Authors' reply	26
Letter: Zinc and Selenium—Potential Biomarkers for Chronic Liver Disease? Authors' Reply	26
Hepatic Events During Immune Checkpoint Inhibitor Treatment Between Liver and Non‐Liver Malignancies in Hepatitis B Endemic Areas	25
Letter: safety of immune checkpoint inhibitors in patients with pre‐established microscopic colitis—a single‐centre experience	25
Letter: association between COVID‐19 and inflammatory bowel disease	25
	25
Faecal incontinence: Retentive, non‐retentive and when to suspect organic pathology	25
Letter: Role of Helicobacter pylori and metabolic syndrome‐related insulin resistance and lipotoxicity in the pathogenesis of MAFLD and MASH—Authors’ reply	25
Letter: 1‐kestose, the smallest fructooligosaccharide component, protection for mild to moderate ulcerative colitis patients	24
Letter: Irritable bowel syndrome and antibiotics—Authors' reply	24
	24
Hepatobiliary disease after bone marrow transplant: A cross‐sectional study of 377 patients	24
Letter: budesonide for functional dyspepsia with duodenal eosinophilia—randomised, double‐blind, placebo‐controlled parallel‐group trial	24
Letter: COVID‐19 outcomes and anti‐TNF treatments—comprehensive evidence matters	23
Systematic review: Defining, diagnosing and monitoring small bowel strictures in Crohn's disease on intestinal ultrasound	23
Trends in the prevalence rates and predictive factors of coeliac disease: A long‐term nationwide follow‐up study	23
Letter: Comparing the Efficacy of Adjuvant PD–1 Inhibitor After Curative Resection for Metabolic Dysfunction‐Associated Steatotic Liver Disease Related HCC Versus Other Aetiologi	23
Review article: current and emerging therapies for acute alcohol‐associated hepatitis	23
Systematic review: Clinical phenotypes, histopathological features and prognosis of enteropathy due to angiotensin II receptor blockers	23
Randomised clinical trial: Design of the SYNERGY‐NASH phase 2b trial to evaluate tirzepatide as a treatment for metabolic dysfunction‐associated steatohepatitis and modification of screening strategy	23
Letter: Modifying the Mayo endoscopic subscore for improved prognostic insights. Authors' reply	23
Systematic review: The use of large language models as medical chatbots in digestive diseases	23
Trends in aetiology‐based hospitalisation for cirrhosis before and during the COVID‐19 pandemic in the United States	23
Low liver fat in non‐alcoholic steatohepatitis‐related significant fibrosis and cirrhosis is associated with hepatocellular carcinoma, decompensation and mortality	22
	22
Editorial: potassium‐competitive acid blockers—is there a role for more complete acid suppression?	22
Letter: assessment of histological disease activity in Crohn's disease clinical trials—a step in the right direction, but further optimisation needed	22
Letter: Safety after cessation of nucleos(t)ide analogue therapy in patients with chronic hepatitis B infection—Authors' reply	22
Systematic review with meta‐analysis: the long‐term efficacy of Barrett's endoscopic therapy—stringent selection criteria and a proposal for definitions	22
CAMP‐B score predicts the risk of hepatocellular carcinoma in patients with chronic hepatitis B after HBsAg seroclearance	22
Review article: Risk of cardiovascular events in patients with inflammatory bowel disease receiving small molecule drugs	22
Editorial: group‐based hypnotherapy as good as individually delivered hypnotherapy for symptoms of irritable bowel syndrome—authors' reply	22
Limited evidence of moderation of the association between gastrointestinal symptoms and prospective healthcare utilisation by quality of life	22
Letter: neuromodulators in functional dyspepsia—the right indication in the right dose. Authors’ reply	22
Editorial: PPIs and gastric cancer – Are we dealing with a carcinogen? Authors' reply	22
Editorial: improving the use of Montreal classification through a bidirectional approach	22
Machine learning liver histology scores correlate with portal hypertension assessments in nonalcoholic steatohepatitis cirrhosis	22
Prevalence of steatotic liver disease, MASLD, MetALD and significant fibrosis in people with HIV in the United States	22

Editorial: lack of gastrointestinal symptoms caused by gluten in patients without coeliac disease—time to ditch the ‘gluten’ from ‘non‐coeliac gluten sensitivity’	22
Editorial: achievements and unresolved questions in improving the pharmacokinetics of vedolizumab in adolescents with inflammatory bowel disease	22
Editorial: higher concentrations of cytokine blockers are needed to obtain small bowel mucosal healing during maintenance therapy in Crohn's disease	22
Editorial: DoesESWL‐ERCPfor pancreatic duct stone removal change the natural course of symptomatic chronic calcific pancreatitis?	22
Issue Information	22
	21
Letter: Shifting focus—From ChatGPT to specialised medical LLMs	21
Treatment of inflammatory bowel disease with steroid‐sparing medications is age‐dependent – Results from a Danish nationwide cohort study, 2000–2018	21
Editorial: Variceal Bleeding in Patients Receiving Atezolizumab–Bevacizumab for Hepatocellular Carcinoma—Don't Ignore the Risk Factors! Authors' Reply	21
Real‐world comparison of effectiveness between tofacitinib and vedolizumab in patients with ulcerative colitis exposed to at least one anti‐TNF agent	21
	21
Editorial: The Relevance of Hepatic Flares and Quantitative Hepatitis B Surface Antigen After Stopping HBV Polymerase Inhibitors—Authors' Reply	21
Meta‐analysis: analysis of mechanistic pathways in the treatment of non‐alcoholic steatohepatitis. Evidence from a Bayesian network meta‐analysis	21
Editorial: Can We Modify the Development and Disease Course of Inflammatory Bowel Disease by Diet?	21
Significant histological disease of patients with chronic hepatitis B virus infection in the grey zone	20
Editorial: implications and future perspectives of the increase in biologics use in paediatric inflammatory bowel disease	20
Racial and ethnic differences in diet quality and food insecurity among adults with fatty liver and significant fibrosis: a U.S. population‐based study	20
Incidence, outcomes, and impact of COVID‐19 on inflammatory bowel disease: propensity matched research network analysis	20
Home‐based, tunnelled peritoneal drainage system as an alternative treatment option for patients with refractory ascites	20
Editorial: The use of Baveno VI and VII criteria in patients with hepatocellular carcinoma	20
Editorial: One step closer to personalised nutrition therapy for irritable bowel syndrome	20
Systematic review with meta‐analysis: The effects of non‐steroidal anti‐inflammatory drugs and anti‐platelet therapy on the incidence and recurrence of hepatocellular carcinoma	20
Age at treatment initiation predicts response in children with chronic hepatitis B	20
Type 1 diabetes and microscopic colitis: A nationwide matched case–control study in Sweden	20
Letter: universal screening for hepatitis C in pregnant women, children and adolescents	20
Association of High‐Sensitivity Troponins in Metabolic Dysfunction‐Associated Steatotic Liver Disease With All‐Cause and Cause‐Specific Mortality	20
No association between chronic use of ranitidine, compared with omeprazole or famotidine, and gastrointestinal malignancies	20
Effect of time to pre‐emptive transjugular intrahepatic portosystemic shunt on patient outcome, a UK multicentre cohort study	20
Systematic review with meta‐analysis: artificial intelligence in the diagnosis of oesophageal diseases	20
Editorial: safety of thiopurines in pregnancy—considering the mother, foetus and newborn	19
	19
Systematic review with meta‐analysis: effects of implementing a nutrition support team for in‐hospital parenteral nutrition	19
Letter: Bif195 for aspirin‐induced gastric mucosal damage – More to do in further research. Authors' reply	19
Novel microbiome signatures for non‐invasive diagnosis of adenoma recurrence after colonoscopic polypectomy	19
	19
Letter: mind the gap—search and publication date of systematic reviews and meta‐analysis. Authors' reply	19
Editorial: Updated epidemiology of steatotic liver disease in people with HIV in the United States	19
Letter: Should ulcerative colitis be monitored more or less invasively?	19
Early serum ammonia variation in critically ill patients with cirrhosis: A multicentre cohort study	19
Risk of colorectal neoplasia according to histologic disease activity in patients with inflammatory bowel disease and colonic post‐inflammatory polyps	19
Letter: efficacy of peppermint oil in irritable bowel syndrome—authors' reply	19
Editorial: work and activity impairment are important considerations to optimise treatment plans for irritable bowel syndrome	19
Letter: efficacy of peppermint oil in irritable bowel syndrome	19
Editorial: Viral hepatitis elimination: Still a big challenge: Care is not only for C	19
Baseline Drug Clearance Predicts Outcomes in Children With Inflammatory Bowel Disease Treated With Vedolizumab: Results From the VedoKids Prospective Multicentre Study	19
Editorial: Trajectory of soluble programmed cell death protein‐1 and ligand‐1 in HBV‐infected individuals treated with pegylated interferon—Implications for stopping rules and the HBV<	19
Editorial: coeliac disease follow‐up guided by gluten immunogenic peptides—are we there yet?	18
Real‐Time Assessment of H. pylori Infection to Guide Molecular Antibiotic Resistance Testing: A Combined Endoscopy‐Gastric Juice Analysis Approach	18
Increased risk of hepatocellular carcinoma and mortality in chronic viral hepatitis with concurrent fatty liver	18
Review article: Faecal biomarkers for assessing small intestinal damage in coeliac disease and environmental enteropathy	18
Letter: Low to moderate alcohol intake and progression of non‐alcoholic fatty liver disease	18
Letter: 1‐kestose, the smallest fructooligosaccharide component, protection for mild to moderate ulcerative colitis patients—authors’ reply	18
Review article: A practical approach to persistent gastrointestinal symptoms in inflammatory bowel disease in remission	18
Editorial: trends in paediatric inflammatory bowel disease attributable direct costs	18
Issue Information	18
Editorial: the other bug	18
Letter: Dietary emulsifiers and intestinal health—The beginning of an evolving story: Authors’ reply	18
Natural history and impact of irritable bowel syndrome‐type symptoms in inflammatory bowel disease during 6 years of longitudinal follow‐up	18
Letter: predictive role of magnetic resonance elastography in chronic liver disease – still a long way to go	18
Superficial oesophageal mucosal innervation may contribute to severity of symptoms in oesophageal motility disorders	18
Editorial: optimising hepatitis B vaccine response in inflammatory bowel disease—time to get some skin in the game. Authors' reply	17
Letter: PCSK9 inhibitor for liver transplant patients during the post‐statin era?	17
Review article: Emerging and current management of acute‐on‐chronic liver failure	17
Editorial: non‐erosive reflux disease is often not GERD—time to change the definition or abandon the term?	17
Letter: is there no conclusive evidence for the effect of tranexamic acid on mortality in gastrointestinal bleeding?	17
Editorial: immunosuppression and SARS‐CoV‐2 vaccination—where do we stand?	17
Editorial: bacterial gut symbionts as live biotherapeutic agents in IBS—a rosy future despite potential long‐term safety concerns. Authorsʼ reply	17
Issue Information	17
Editorial: predictors of disease activity during pregnancy in women with inflammatory bowel disease—a Danish cohort study	17
Editorial: The use of Baveno VI and VII criteria for portal hypertension and varices in patients with hepatocellular carcinoma—Authors' reply	17
Epidemiology and risk factors for histopathologic characteristics of non‐alcoholic fatty liver disease in South America	16
Editorial: COVID‐19 vaccines are safe and effective in patients with inflammatory bowel disease—but many unanswered questions remain	16
Timely Follow‐Up After a First Diagnosis of Cirrhosis is Associated With Reduced Mortality but No Impact on Rehospitalisations: A Population‐Based Cohort of 8852 Patients	16
Editorial: the burden of alcohol‐related liver disease emergency admissions in England may be twice as high as previously thought—authorsʼ reply	16
Editorial: Faecal microbiota transplantation inIBS—Moving closer or away from success? Authors' reply	16
	16
Editorial: colorectal cancer in elderly‐onset inflammatory bowel disease—what is the risk?	16
Presence of high‐risk HLA genotype is the most important individual risk factor for coeliac disease among at‐risk relatives	16
Increased spine bone density in patients with chronic hepatitis B switched to tenofovir alafenamide: A prospective, multinational study	16
Letter: fighting the battle but losing the war—inflammatory bowel disease and venous thromboembolism. Authors' reply	16
Letter: 5‐aminosalicylate maintenance treatment in mild Crohn's disease	16
Issue Information	16
Dietary factors and patterns in relation to risk of later‐onset ulcerative colitis in Chinese: A prospective study of 0.5 million people	16
Editorial: Evaluating the Prevalence of Metabolic Dysfunction‐Associated Steatotic Liver Disease in Patients With Type 2 Diabetes and Hyperferritinaemia—Authors' Reply	16
Editorial: Time to address quality of life in our IBD treatment—IBD nurse intervention as a key part of multimodal IBD management	16
Editorial: evolution of GLP‐1 receptor agonists as pharmacotherapy for NASH beyond diabetes mellitus and obesity – authors’ reply	16
Letter: Switching to tenofovir alafenamide for nucleos(t)ide analogue‐experienced patients with chronic hepatitis B can increase body weight—Authors' reply	16
Editorial: Bile acid diarrhoea – simplified clinico‐biochemical diagnosis	15
Repeatability of vibration‐controlled transient elastography versus magnetic resonance elastography in patients with cirrhosis: A prospective study	15
Editorial: ‘Risk‐Adapted Starting Ages of Colorectal Cancer Screening for People With Diabetes or Metabolic Syndrome’	15
Prevalence and prognosis of patients with MASLD‐related cirrhosis after an ICU hospitalization in France: A single‐centre prospective study	15
Quantitative MRCP and metrics of bile duct disease over time in patients with primary sclerosing cholangitis: A prospective study	15
Randomised clinical trial: Pemafibrate, a novel selective peroxisome proliferator‐activated receptor α modulator (SPPARMα), versus placebo in patients with non‐alcoholic fatty liver disease	15
Systematic review and network meta‐analysis: efficacy of licensed drugs for abdominal bloating in irritable bowel syndrome with constipation	15
Glycaemic control is a modifiable risk factor for hepatocellular carcinoma and liver‐related mortality in patients with diabetes	15